Spike Health Attends the Show
Release time:
2020-08-14
Peak Health Attends Exhibition
US Natural, Health and Innovative Raw Materials Exhibition (US East Exhibition)
News from our newspaper 4# September 18 - 20 , sponsored by Informa Exhibition 2017 American Natural, Healthy and Innovative Raw Materials Exhibition (Meidong Exhibition) was successfully held in Orlando, USA. spike health technology company with ginkgo biloba extract, rhodiola extract, cranberry extract and other products to participate in the exhibition.
American plant extract professional supplier exhibition is the largest international exhibition of natural extracts, pharmaceutical raw materials, fine chemical raw materials and intermediates, cosmetics, nutrition and health products and food additives in the United States. Each year, it is held in the eastern and western regions of the United States respectively. The 2017 Eastern Exhibition was held in Orlando, attracting more than ,500 enterprises from all over the world to participate in the exhibition. Among them, there are more than ,60 Chinese enterprises, with more than ,000 professional audiences and an exhibition area of more than ,10000 square meters.
Jianfeng Health adheres to the business philosophy of "green, natural, healthy and safe", and focuses on the introduction of extract products such as ginkgo biloba, rhodiola, cranberry, wolfberry and cinnamon at this exhibition. There is an endless stream of customers who come to negotiate and consult, and some old customers come to the booth to communicate and further deepen their understanding. A number of U.S. local nutrition and health care companies have also expressed interest in Jianfeng Health's products, including Now Foods and other well-known health care and food companies, which have laid a certain foundation for Jianfeng Health to further enter and develop the U.S. health care raw material market. On the opening day of the
exhibition, the organizers of the exhibition also specially organized a group of Chinese exhibitors to lead the group of buyers to have a face-to-face special exchange with Jianfeng Health. The staff introduced the peak health technology company and products in detail, which further improved the international influence and reputation of peak health in the professional field of plant extraction, and achieved good publicity effect. This exhibition fully demonstrated the good image of peak health, demonstrated the strength of the enterprise, and made customers and peers feel the professionalism, dedication and sincerity of peak health more intuitively. (Wang Zhen)
World Expo
News 4 17 - 19 World Expo 2017 21st China International Nutrition and Health Industry Expo (Spring Exhibition) was held in Beijing China International Exhibition Center, spike Health Technology Company participated in the exhibition to promote products.
Expo Wei Health Expo has built up a procurement database of buyers in health food related fields in 28 countries and regions in the world through more than 10 years of accumulation. It has been rated by the Ministry of Commerce as the only key exhibition supported by the government in China's health field, and is recognized by the health industry as a large-scale, effective and popular industry event in Asia. This Expo has attracted nearly 1,000 enterprises from more than 20 countries and 10 exhibition groups to jointly outline the blueprint for the big health industry. Spike health booth scene atmosphere lively, crowded, visiting customers in an endless stream.
This exhibition not only showcases the products and technologies of Spike Health, but also further enhances the visibility and influence of Spike Health brand in the industry. (Jia Xiaowei)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page